Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study

Bains, Simer Jit; Mahic, Milada; Myklebust, Tor Åge; Småstuen, Milada Cvancarova; Yaqub, Sheraz; Dørum, Liv Marit; Bjørnbeth, Bjørn Atle; Møller, Bjørn; Brudvik, Kristoffer Watten; Taskén, Kjetil

doi:10.1200/jco.2015.65.3519

Cited by 64 publications

(73 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, our results confirmed that SII is indeed superior to PLR, NLR and MLR. In addition, many studies have confirmed that non-steroidal anti-inflammatory drugs (NSAIDs) are associated with improved survival outcomes in patients with cancer, including esophageal cancer2526. The patients with ESCC who have a high SII maybe especially benefit from targeted anti-inflammatory with aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).…”

Section: Discussionmentioning

confidence: 99%

Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Geng

Shao

Zhu

et al. 2016

Sci Rep

207

171

View full text Add to dashboard Cite

Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, was recently investigated as a prognostic marker in several tumors. However, SII has not been reported in esophageal squamous cell carcinoma (ESCC). We evaluated the prognostic value of the SII in 916 patients with ESCC who underwent radical surgery. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. The time-dependent receiver operating characteristics (ROC) curve was used to compare the discrimination ability for OS. PSM (propensity score matching) was carried out to imbalance the baseline characteristics. Our results showed that SII, PLR, NLR and MLR were all associated with OS in ESCC patients in the Kaplan-Meier survival analysis. However, only SII was an independent risk factor for OS (HR = 1.24, 95% CI 1.01–1.53, P = 0.042) among these systemic inflammation scores. The AUC for SII was bigger than PLR, NLR and MLR. In the PSM analysis, SII still remained an independent predictor for OS (HR = 1.30, CI 1.05–1.60, P = 0.018). SII is a novel, simple and inexpensive prognostic predictor for patients with ESCC undergoing radical esophagectomy. The prognostic value of SII is superior to PLR, NLR and MLR.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Geng

Shao

Zhu

et al. 2016

Sci Rep

207

171

View full text Add to dashboard Cite

show abstract

“…Targeted agents that regulate inflammation and immunity may improve the prognosis of patients with immune-mediated diseases. Aspirin was demonstrated to be helpful in protecting patients with chronic hepatitis from HCC [30] and could also be effective as secondary prevention in patients with colorectal cancer [31]. Thymosin has shown antitumor effects via enhancement of the Th1 immune response [32].…”

Section: Discussionmentioning

confidence: 99%

Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria

Zheng

Cai

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: There is growing evidence that the systemic immune-inflammation index (SII), a novel prognostic biomarker based on peripheral lymphocyte, neutrophil, and platelet counts, is associated with poor prognosis for several tumors. However, the prognostic value of SII in patients with hepatocellular carcinoma (HCC) who undergo liver transplantation (LT) remains unclear. The aim of this study was to determine the correlation between SII and prognosis in these patients. Methods: This retrospective study involved 150 patients with HCC who underwent LT within the Hangzhou criteria. The optimal cut-off value was determined by receiver-operating characteristic (ROC) curve analysis to stratify the patients into those with a high SII and those with low SII. The Kaplan-Meier method and the Cox proportional hazards model were used to evaluate the prognostic value of SII. Finally, we calculated the area under the ROC curve to compare the prognostic power of SII, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). Results: Patients were divided into high SII (≥ 226) and low SII (< 226) groups. Five-year overall survival (OS) was lower in the high SII group than in the low SII group (56.1% vs. 82.4%, p = 0.002). SII ≥ 226 × 109/L, maximum tumor size> 5 cm, microvascular invasion, and poor differentiation were independent prognostic factors for OS. However, SII did not predict 5-year recurrence-free survival (high vs. low SII: 64.1% vs. 78.4%, p = 0.073). The area under the ROC curve was greater for SII than for PLR, NLR, and MLR. Conclusions: Preoperative SII may be a powerful prognostic biomarker in patients with HCC who undergo LT within the Hangzhou criteria. SII is superior to PLR, NLR, and MLR for prediction of OS in these patients.

show abstract

“…In recent decades, there have been many studies on aspirin and its effectiveness in the treatment of colorectal cancer. In pre‐clinical studies, aspirin has been found to reduce the incidence of CRC and it is used as secondary prevention in patients with CRC . Aspirin can inhibit cell proliferation and pro‐apoptosis in several tumour‐derived cell lines, the mechanism of which is through the inhibition of the Wnt/β‐catenin pathway, vascular endothelial growth factor (EGFR) activation, NF‐κB and COX‐2 expression …”

Section: Introductionmentioning

confidence: 99%

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway

Duan

Zhou

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most widespread malignant cancers, with a high incidence and mortality all over the world. Aspirin (ASA) otherwise known as acetylsalicylic acid, is a non‐steroidal anti‐inflammatory drug that has shown promising results in the prevention of chronic diseases, including several cancers. In previous studies, aspirin has been shown to reduce the incidence of CRC. Immune checkpoint blockade of T cell Ig and ITIM domain receptor (TIGIT) alone or combined with other immune checkpoint blockades moleculars has gained impressive results in the treatment of the melanoma and glioblastoma. Here, we found that TIGIT and Poliovirus receptor (PVR, CD155) are expressed in tumour cells; the TIGIT and CD155 protein expression in cancer tissue has been found to be significantly higher than that in the precancerous tissue. T cell Ig and ITIM domain receptor and CD226 were expressed in the lymphocytes near the tumour tissue and the adjacent tissues. Aspirin has been found to inhibit cancer cell viability and promote CRC cell apoptosis.Similarly, aspirin has also been found to increase pro‐apoptotic protein Bax's expression. We found that the expression of TIGIT decreased with an increase in the concentration of aspirin and that the suppression of TIGIT can affect the effect of aspirin on cell proliferation. In this paper, we found that aspirin attenuates cancer cell proliferation and induces CRC cells apoptosis by down‐regulating the expression of TIGIT, which provides new evidence for the application of aspirin in cancer treatment.

show abstract

Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study

Abstract: Aspirin use after the diagnosis of CRC is independently associated with improved CSS and OS.

Cited by 64 publications

References 21 publications

Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis

Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria

Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway

Contact Info

Product

Resources

About